Mechanisms of anti-cancer effects of ascorbate: Cytotoxic activity and epigenetic modulation
/in International Publications, Micronutrients /von 2017-09-21 / Blood Cells Mol. Dis. 2018 03;69:57-64Comparing the Effectiveness of Combined External Beam Radiation and Hyperthermia Versus External Beam Radiation Alone in Treating Patients With Painful Bony Metastases: A Phase 3 Prospective, Randomized, Controlled Trial
/in Hyperthermia, International Publications /von 2017-09-21 / Int. J. Radiat. Oncol. Biol. Phys. 2018 01;100(1):78-87Increased cycles of DC/CIK immunotherapy decreases frequency of Tregs in patients with resected NSCLC
/in Dendritic Cells, International Publications, NSCLC /von 2017-09-21 / Int. Immunopharmacol. 2017 Nov;52:197-202Curing glioblastoma: oncolytic HSV-IL12 and checkpoint blockade
/in Checkpoint-Inhibitors, Glioblastoma, International Publications, Newcastle Disease Virus /von 2017-09-20 / Oncoscience 2017 Jul;4(7-8):67-69Genetically engineered oncolytic Newcastle disease virus mediates cytolysis of prostate cancer stem like cells
/in International Publications, Newcastle Disease Virus, Prostate Cancer /von 2017-09-19 / J. Biotechnol. 2017 Oct;260:91-97Flüssigbiopsie: Symposium zum Thema Liquid Biopsies & Cancer, Leuven Cancer Institute
/0 Kommentare/in Externe Meldungen /von IOZKNewcastle disease virus mediates pancreatic tumor rejection via NK cell activation and prevents cancer relapse by prompting adaptive immunity
/in International Publications, Newcastle Disease Virus, Pancreatic Cancer /von 2017-09-13 / Int. J. Cancer 2017 12;141(12):2505-2516Hematologic neoplasms: Dendritic cells vaccines in motion
/in Dendritic Cells, International Publications /von 2017-09-12 / Clin. Immunol. 2017 10;183:181-190Oncolytic Viruses-Interaction of Virus and Tumor Cells in the Battle to Eliminate Cancer
/in International Publications, Newcastle Disease Virus /von 2017-09-08 / Front Oncol 2017;7:195
IMMUN-ONKOLOGISCHES ZENTRUM KÖLN
Hohenstaufenring 30–32
50674 Köln | Deutschland
T: +49 (0)221 – 420 399 25
E-Mail: info@iozk.de
Hohenstaufenring 30–32
50674 Köln | Deutschland
T: +49 (0)221 – 420 399 25
E-Mail: info@iozk.de
Das IOZK
Die IOZK Immuntherapie
Aktuelles und Int. Publikationen
- Recent developments in targeting breast cancer stem cells (BCSCs): a descriptive review of therapeutic strategies and emerging therapies
- Neoantigen-targeted dendritic cell vaccination in lung cancer patients induces long-lived T cells exhibiting the full differentiation spectrum
- Individualized Multimodal Immunotherapy (IMI): Scientific Rationale and Clinical Experience from a Single Institution